PortalPublikationenHuman kallikrein 8 protein is a favorable prognostic marker ...

Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer

Standard

Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. / Borgoño, Carla A; Kishi, Tadaaki; Scorilas, Andreas; Harbeck, Nadia; Dorn, Julia; Schmalfeldt, Barbara; Schmitt, Manfred; Diamandis, Eleftherios P.

in: CLIN CANCER RES, Jahrgang 12, Nr. 5, 01.03.2006, S. 1487-93.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Borgoño, CA, Kishi, T, Scorilas, A, Harbeck, N, Dorn, J, Schmalfeldt, B, Schmitt, M & Diamandis, EP 2006, 'Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer', CLIN CANCER RES, Jg. 12, Nr. 5, S. 1487-93. https://doi.org/10.1158/1078-0432.CCR-05-2106

APA

Borgoño, C. A., Kishi, T., Scorilas, A., Harbeck, N., Dorn, J., Schmalfeldt, B., Schmitt, M., & Diamandis, E. P. (2006). Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. CLIN CANCER RES, 12(5), 1487-93. https://doi.org/10.1158/1078-0432.CCR-05-2106

Vancouver

Borgoño CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B et al. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. CLIN CANCER RES. 2006 Mär 1;12(5):1487-93. https://doi.org/10.1158/1078-0432.CCR-05-2106

Bibtex

@article{7f337259f7dc466f93d90ed5ff4f4bef,
title = "Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer",
abstract = "Human kallikrein 8 (hK8/neuropsin/ovasin; encoded by KLK8) is a steroid hormone-regulated secreted serine protease differentially expressed in ovarian carcinoma. KLK8 mRNA levels are associated with a favorable patient prognosis and hK8 protein levels are elevated in the sera of 62% ovarian cancer patients, suggesting that KLK8/hK8 is a prospective biomarker. Given the above, the aim of the present study was to determine if tissue hK8 bears any prognostic significance in ovarian cancer. Using a newly developed ELISA, hK8 was quantified in 136 ovarian tumor extracts and correlated with clinicopathologic variables and outcome [progression-free survival (PFS); overall survival (OS)] over a median follow-up period of 42 months. hK8 levels in ovarian tumor cytosols ranged from 0 to 478 ng/mg total protein, with a median of 30 ng/mg. An optimal cutoff value of 25.8 ng/mg total protein (74th percentile) was selected based on the ability of hK8 values to predict the PFS of the study population and to categorize tumors as hK8 positive or negative. Women with hK8-positive tumors most often had lower-grade tumors (G1), no residual tumor after surgery, and optimal debulking success (P < 0.05). Univariate and multivariate analyses revealed that patients with hK8-positive tumors had a significantly longer PFS and OS than hK8-negative patients (P < 0.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK8-positive tumors (P = 0.001 and P = 0.014, respectively). These results indicate that hK8 is an independent marker of favorable prognosis in ovarian cancer.",
keywords = "Adenocarcinoma, Clear Cell, Adenocarcinoma, Mucinous, Adult, Aged, Aged, 80 and over, CA-125 Antigen, Carcinoma, Endometrioid, Cystadenocarcinoma, Serous, Disease Progression, Disease-Free Survival, Female, Gene Expression Regulation, Neoplastic, Humans, Kallikreins, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Prognosis, Survival Rate, Tumor Markers, Biological",
author = "Borgo{\~n}o, {Carla A} and Tadaaki Kishi and Andreas Scorilas and Nadia Harbeck and Julia Dorn and Barbara Schmalfeldt and Manfred Schmitt and Diamandis, {Eleftherios P}",
year = "2006",
month = mar,
day = "1",
doi = "10.1158/1078-0432.CCR-05-2106",
language = "English",
volume = "12",
pages = "1487--93",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer

AU - Borgoño, Carla A

AU - Kishi, Tadaaki

AU - Scorilas, Andreas

AU - Harbeck, Nadia

AU - Dorn, Julia

AU - Schmalfeldt, Barbara

AU - Schmitt, Manfred

AU - Diamandis, Eleftherios P

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Human kallikrein 8 (hK8/neuropsin/ovasin; encoded by KLK8) is a steroid hormone-regulated secreted serine protease differentially expressed in ovarian carcinoma. KLK8 mRNA levels are associated with a favorable patient prognosis and hK8 protein levels are elevated in the sera of 62% ovarian cancer patients, suggesting that KLK8/hK8 is a prospective biomarker. Given the above, the aim of the present study was to determine if tissue hK8 bears any prognostic significance in ovarian cancer. Using a newly developed ELISA, hK8 was quantified in 136 ovarian tumor extracts and correlated with clinicopathologic variables and outcome [progression-free survival (PFS); overall survival (OS)] over a median follow-up period of 42 months. hK8 levels in ovarian tumor cytosols ranged from 0 to 478 ng/mg total protein, with a median of 30 ng/mg. An optimal cutoff value of 25.8 ng/mg total protein (74th percentile) was selected based on the ability of hK8 values to predict the PFS of the study population and to categorize tumors as hK8 positive or negative. Women with hK8-positive tumors most often had lower-grade tumors (G1), no residual tumor after surgery, and optimal debulking success (P < 0.05). Univariate and multivariate analyses revealed that patients with hK8-positive tumors had a significantly longer PFS and OS than hK8-negative patients (P < 0.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK8-positive tumors (P = 0.001 and P = 0.014, respectively). These results indicate that hK8 is an independent marker of favorable prognosis in ovarian cancer.

AB - Human kallikrein 8 (hK8/neuropsin/ovasin; encoded by KLK8) is a steroid hormone-regulated secreted serine protease differentially expressed in ovarian carcinoma. KLK8 mRNA levels are associated with a favorable patient prognosis and hK8 protein levels are elevated in the sera of 62% ovarian cancer patients, suggesting that KLK8/hK8 is a prospective biomarker. Given the above, the aim of the present study was to determine if tissue hK8 bears any prognostic significance in ovarian cancer. Using a newly developed ELISA, hK8 was quantified in 136 ovarian tumor extracts and correlated with clinicopathologic variables and outcome [progression-free survival (PFS); overall survival (OS)] over a median follow-up period of 42 months. hK8 levels in ovarian tumor cytosols ranged from 0 to 478 ng/mg total protein, with a median of 30 ng/mg. An optimal cutoff value of 25.8 ng/mg total protein (74th percentile) was selected based on the ability of hK8 values to predict the PFS of the study population and to categorize tumors as hK8 positive or negative. Women with hK8-positive tumors most often had lower-grade tumors (G1), no residual tumor after surgery, and optimal debulking success (P < 0.05). Univariate and multivariate analyses revealed that patients with hK8-positive tumors had a significantly longer PFS and OS than hK8-negative patients (P < 0.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK8-positive tumors (P = 0.001 and P = 0.014, respectively). These results indicate that hK8 is an independent marker of favorable prognosis in ovarian cancer.

KW - Adenocarcinoma, Clear Cell

KW - Adenocarcinoma, Mucinous

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - CA-125 Antigen

KW - Carcinoma, Endometrioid

KW - Cystadenocarcinoma, Serous

KW - Disease Progression

KW - Disease-Free Survival

KW - Female

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Kallikreins

KW - Middle Aged

KW - Neoplasm Staging

KW - Ovarian Neoplasms

KW - Prognosis

KW - Survival Rate

KW - Tumor Markers, Biological

U2 - 10.1158/1078-0432.CCR-05-2106

DO - 10.1158/1078-0432.CCR-05-2106

M3 - SCORING: Journal article

C2 - 16533772

VL - 12

SP - 1487

EP - 1493

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 5

ER -